Search

everythinglearnresearchcommunity

for

Search:↓

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.

Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Flutamide helps with prostate cancer and some skin conditions but can harm the liver.

Teriflunomide is effective and generally safe for treating relapsing multiple sclerosis, reducing relapse rates and disability progression.

Ruxolitinib cream effectively treats skin conditions like atopic dermatitis and vitiligo with minimal side effects.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Tislelizumab can cause cutaneous lupus erythematosus.

Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.

9-cis-retinoic acid showed some effectiveness in treating AIDS-related Kaposi sarcoma but had significant side effects at higher doses.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Ritlecitinib significantly regrows scalp hair in people with alopecia areata.

Blocking CRF1 receptors improved male hormone levels and reduced testicular tumor size in men with a specific adrenal condition.

Rituximab leads to longer remission and fewer side effects than cyclophosphamide.

Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.

A patient with lupus and long-term hair loss saw significant hair regrowth after using the drug tofacitinib.

QLT0267 stops hair follicle cell growth and movement.

Ritlecitinib improves hair regrowth in alopecia areata over 24 months.